skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

医療用医薬品・医療機器産業の経営層向けニュース

In Vivo(インビボ)は主に「成長」「イノベーション」「リーダーシップ」「マーケットアクセス」「マーケットインテリジェンス」の5つの観点から世界の医療用医薬品産業のトレンドを取材しています。

世界の開発パイプラインを分析したインフォーマ・ファーマインテリジェンス発行のレポート「Pharma R&D Annual Review 2018」によると、日本は創薬能力では世界第2位、市場規模でも3位につけています。欧米の新薬創出国と比較して劣っているわけではありません。

一方で世界の大手医薬品企業の経営幹部は、激しい国際競争を勝ち抜くために最新情報を常に把握し、戦略的思考で成長の機会をうかがっています。

In Vivoを読むことによって、経営に携わる人々は根拠をもって意思決定をし、リスクをコントロールできるようになります。In Vivoは今日の経営層または新規ビジネス開発担当者にとっては必須のビジネスツールです。

経営戦略・トップマネジメントの視点から研究開発や財務戦略なども含む医薬品産業ニュースを読めるのはIn Vivoだけです。特集記事、注目の人物、KOLの独占インタビュー、業界幹部の異動情報なども充実しています。

無料トライアルをぜひご利用ください。

このサービスの特徴

無料の最新記事&レポート

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Pharma Intelligence Insights – Outlook 2021 Report

    Power your strongest strategy for the year ahead with insights from the Outlook 2021 report. A combination of Scrip’s Scrip 100, Medtech Insight’s Medtech 100, and In Vivo’s Outlook reports, Outlook 2021 is a comprehensive window into the key trends, challenges and opportunities impacting the biopharma, medtech, and generics sectors for the year to come.

    Topic Outlook

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

    effective-relief

    The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

    Topic Coronavirus Business Strategies Deals

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets. 

    Topic brexit policy-and-regulation

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    From US To EU: Young Biotechs Going It Alone

    Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

    Topic Market Access Rare Diseases Strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    FDA Emphasizes Clinical Trial Flexibility During Coronavirus Pandemic

    FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause. 

    Topic Coronavirus fda

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

    Topic Financing strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    COVID-19 Vaccine Expectations Are Ambitious Not Impossible

    invivo-COVID-19 Vaccine Expectations Are Ambitious Not Impossible

    Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.

    Topic Coronavirus vaccines

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Curing What Hinders Alzheimer’s Drug Development

    Curing What Hinders Alzheimer’s Drug Development

    Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

    Topic alzheimers drug-development-landscape

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

    Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

    Topic business-strategies Leadership

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    A Tale Of Two Pipelines

    A_Tale_Of_Two_Pipelines_1

    Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

    Topic Cancer Research & Development

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Medtech Insight: 世界の医療機器・医...

    Transforming Cancer Treatment with Early Detection Diagnostics: Opportunities And Obstacles Webinar

    Join distinguished cancer and industry experts as they explore what a shift in cancer treatment – from late stage intervention to an early detection paradigm – would mean for patient outcomes, cancer costs, technology, development, regulatory affairs, and more. Explore this new approach toward focusing on early stage cancer detection, including discussion of diagnostics in this area, such as biomarker identification, liquid biopsies, and monitoring technologies.

    Topic Diagnostics cancer

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Scrip: 世界の医療用医薬品&製薬産業に関するニ...

    BIO-Europe Biopharma Deals and Financing eBook

    BIO-Europe Biopharma Deals and Financing eBook

    2020 coverage from Scrip and In Vivo provides rich insights into the attitudes and trends around deals and financing, two major engines of innovation and growth for biopharma during this current pandemic period.

  • Pink Sheet: 世界の薬事規制と承認審査に関するニュース, Scrip: 世界の医療用医薬品&製薬産業に関するニ...

    遺伝子治療の最新動向 – eBook無料ダウンロード

    ますます重要性を増す遺伝子治療分野の最新情報をeBookの形でお届けします。ニュースサービスのScrip, Pink Sheet, In Vivoより、主に以下のトピックをピックアップしました。無料でダウンロードできます。ぜひご覧下さい。

    Topic research deal-trends

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Medtech Insight: 世界の医療機器・医...

    デジタルツールの台頭:eBook無料ダウンロード:

    今回のeBookでは、COVID-19による混乱に対処するために、医薬品産業がデジタルテクノロジーをどのように活用しているのか探りました。規制やガイドラインに関する情報や業界リーダーの動向を紹介することで、今回の危機がもたらす新たな時代の可能性を検証しています。無料でダウンロードできます。ぜひご覧下さい。

    Topic Coronavirus

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    The Sensational Trumps Sense As UK Voters Show Appetite For "Brexit"

    The Sensational Trumps Sense As UK Voters Show Appetite For "Brexit"

    As night turned to day on June 24, it became clearer by the hour that the unthinkable had happened, and the UK’s long and acrimonious debate about its 43-year membership of the European Union had ended in a victory for the Leave group. The local health care products industries made their views clear some weeks ago, but today and in the months to come, they will have to confront a Plan B that was never in the plans.

    Topic Market Access Brexit

医薬品産業専門のジャーナリスト&アナリスト

Editor

William Looney

Editor, Executive Editor, In Vivo

USA

William Looney

William specializes in

  • Biopharma pipeline strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy and Regulation

+40 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly
Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。